onc Videos

Videos

Conference Coverage

Adjuvant Nivolumab Sustains Clinical Benefit for Patients With Resected Stage IIB/IIC Melanoma

10/07/2024

Georgina Long, MD, PhD, discusses 3-year follow-up results from the phase 3 CheckMate 76K trial which demonstrated that adjuvant nivolumab continued to sustain clinical benefit among patients with resected stage IIB/IIC melanoma.

Georgina Long, MD, PhD,...

10/07/2024

Oncology

Conference Coverage

Examining Current and Upcoming Treatment Options for Patients With Low-Risk MDS

10/04/2024

Guillermo Garcia-Manero , MD;

At the 2024 SOHO meeting, Guillermo Garcia-Manero, MD, shared expert insight into treatment options that are available and upcoming for patients with low-risk myelodysplastic syndrome.

At the 2024 SOHO meeting,...

10/04/2024

Oncology

Conference Coverage

Darolutamide Demonstrates Efficacy and Safety for Metastatic Hormone-Sensitive Prostate Cancer

10/02/2024

Fred Saad , MD;

Fred Saad, MD, discusses results from the phase 3 ARANOTE trial which assessed the efficacy and tolerability of adding darolutamide to androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Fred Saad, MD, discusses results...

10/02/2024

Oncology

Conference Coverage

Neoadjuvant Immune Checkpoint Inhibitors Extend Survival Among Patients With Advanced Melanoma

10/01/2024

Georgina Long, MD, PhD, discusses updated pooled analysis results from the International Neoadjuvant Melanoma Consortium which identified that neoadjuvant immunotherapy extends survival in patients with advanced melanoma.

Georgina Long, MD, PhD,...

10/01/2024

Oncology

Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute

Videos

Inavolisib vs Alpelisib Plus Fulvestrant For Patients With PIK3CA-Mutated Advanced Breast Cancer

09/24/2024

Demetria J. Smith-Graziani , MD, MPH;

Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...

Demetria Smith-Graziani, MD,...

09/24/2024

Oncology

Conference Coverage

Should BTK Inhibitor Treatment be Discontinued Among Patients With CLL?

09/23/2024

;

At the 2024 SOHO meeting, Kerry Rogers, MD, participated in a debate in which she argued against discontinuing BTK inhibitor treatment among patients with chronic lymphocytic leukemia.

At the 2024 SOHO meeting, Kerry...

09/23/2024

Oncology

Conference Coverage

Lenvatinib Provides Promising Clinical Benefit in Advanced Gastrointestinal Stromal Tumors

09/18/2024

Jean-Yves Blay, MD, PhD, discusses results from the LENVAGIST study which assessed the clinical efficacy of lenvatinib among patients with advanced gastrointestinal stromal tumors after tyrosine kinase inhibitor failure.

Jean-Yves Blay, MD, PhD,...

09/18/2024

Oncology

Jamie Chaft, MD, Memorial Sloan Kettering Cancer Center

Videos

Updated 5-Year Data From the IMpower010 Trial

09/17/2024

Jamie Chaft , MD;

Jamie Chaft, MD, discusses the 5-year follow-up data from the IMpower010 trial which showed atezolizumab continued to provide greater improvement to disease-free survival than best supportive care for patients with resectable early-stage...

Jamie Chaft, MD, discusses the...

09/17/2024

Oncology

Videos

Updates in Polycythemia Vera Treatment and Management

09/17/2024

Gabriela Hobbs, MD, provides an overview of the latest strategies and updates regarding the management and treatment of patients with polycythemia vera.

Gabriela Hobbs, MD, provides an...

09/17/2024

Oncology

Conference Coverage

Strategic Treatment Regimens Utilizing Approved JAK Inhibitors for Patients With Myelofibrosis

09/17/2024

At the 2024 SOHO meeting, Prithviraj Bose, MD, discusses currently available JAK inhibitors for the treatment of myelofibrosis, highlighting ruxolitinib, fedratinib, pacritinib, and momelotinib.

At the 2024 SOHO meeting,...

09/17/2024

Oncology

Recent News

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology

News

Extended Lymphadenectomy Fails to Improve Survival Outcomes for Patients With Muscle-Invasive Bladder Cancer

11/05/2024

Stephanie Holland ;

Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.

Results from the phase 2 SWOG...

11/05/2024

Oncology

News

Tumor Molecular Features Contribute Substantially to Overall Survival Disparities Among Patients With Colorectal Cancer

11/05/2024

Allison Casey ;

According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.

According to a single-center...

11/05/2024

Oncology

News

First-Line Durvalumab Plus Platinum-Doublet Chemotherapy Prolongs Survival for Patients With Extensive-Stage Small Cell Lung Cancer

11/04/2024

Stephanie Holland ;

According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...

According to results from a...

11/04/2024

Oncology